GlassScriptPhysician profile
Colleen Monaghan
NPI 1255192563
$2,743.21
in general payments reported to CMS, 2019-2025
27 companies · $1,287 in 2025
The $1,287 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $99.16 · 2024: $1,357 · 2025: $1,287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,463 · Long Term Medical Supply Or Device Loan: $1,280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,463.48 |
| Long Term Medical Supply Or Device Loan | $1,279.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,401.66 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $234.14 | 2023-2025 | Calquence, Lynparza, Imfinzi |
| Sobi, INC | $112.04 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $104.25 | 2024-2025 | Libtayo, Lynozyfic |
| Daiichi Sankyo INC. | $87.20 | 2024-2025 | Enhertu |
| Pharmaessentia USA Corporation | $65.51 | 2024-2025 | Besremi |
| Genentech USA, INC. | $60.42 | 2023-2024 | Tecentriq, Polivy, Lunsumio |
| Exelixis INC. | $59.73 | 2024-2025 | Cabometyx |
| Takeda Pharmaceuticals U.S.A., INC. | $55.87 | 2025 | Hyqvia, Fruzaqla |
| Janssen Biotech, INC. | $54.73 | 2024-2025 | Darzalex, Tecvayli, Talvey |
| Eisai INC. | $53.75 | 2024 | |
| Glaxosmithkline, LLC. | $52.76 | 2024 | Zejula, Jemperli |
| Merck Sharp & Dohme LLC | $38.18 | 2024 | Keytruda, Welireg |
| Gilead Sciences, INC. | $37.29 | 2024-2025 | Trodelvy |
| Caris Mpi, INC. | $35.68 | 2025 | Mi Cancer Seek |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Immunocore Limited | $34.55 | 2024 | Kimmtrak |
| Genmab U.S., INC. | $32.98 | 2025 | Epkinly |
| Beigene USA, INC. | $30.29 | 2024 | Brukinsa |
| Beone Medicines USA, INC. | $26.92 | 2025 | Tevimbra |
| Tempus Ai, INC | $26.48 | 2024 | Xt Cdx |
| Spectrum Pharmaceuticals INC. | $24.00 | 2025 | Rolvedon |
| Taiho Oncology, INC. | $22.19 | 2023 | |
| Genzyme Corporation | $21.45 | 2025 | |
| Abbvie INC. | $20.27 | 2025 | |
| Kyowa Kirin, INC. | $20.25 | 2025 | |
| Pharmacosmos Therapeutics INC. | $16.68 | 2025 | Monoferric |
| Geron Corporation | $13.94 | 2025 | Rytelo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colleen Monaghan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.